Tempest Therapeutics, Inc. (TPST)
TPST moved a median of -0.62% 30 minutes after news, and -0.78% by the close. How TPST actually reacts to news — the realized, point-in-time move the market made, measured across 237 labeled events over the last three years with zero look-ahead.
TPST’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.27% | 37% | 236 |
| 30-min | -0.62% | 40% | 237 |
| 60-min | -1.21% | 35% | 237 |
| to close | -0.78% | 44% | 229 |
| Middle 50% of TPST reactions | -3.33% to +2.38% |
|---|---|
| Median reaction (30-min) | -0.62% |
| Measured reactions | 237 |
Half of all Tempest Therapeutics, Inc. news events land between -3.33% and +2.38% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when TPST moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to TPST's baseline. Nothing else.
Recent TPST events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Tempest Therapeutics, For: Oct 14 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form DEFA14A Tempest Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | — | — | |
| Form 8-K Tempest Therapeutics, For: Oct 13 | SEC filing · Form 8-K | SEC EDGAR | +0.25% | -4.05% | |
| Form PRE 14A Tempest Therapeutics, For: Nov 09 | SEC filing · Form PRE | SEC EDGAR | +0.00% | -6.23% | |
| Form D Tempest Therapeutics, | SEC filing · Form D | SEC EDGAR | -2.35% | -8.79% | |
| Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise | Press release | GlobeNewswire | -2.35% | -8.79% | |
| Form EFFECT Tempest Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | +1.94% | -1.54% | |
| Form 8-K Tempest Therapeutics, For: Sep 22 | SEC filing · Form 8-K | SEC EDGAR | -0.98% | -1.85% | |
| Form S-3 Tempest Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | -1.82% | +0.80% | |
| Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors | Press release | GlobeNewswire | +0.35% | -6.78% | |
| Form 8-K Tempest Therapeutics, For: Sep 14 | SEC filing · Form 8-K | SEC EDGAR | +5.88% | +13.88% | |
| Form 8-K Tempest Therapeutics, For: Sep 15 | SEC filing · Form 8-K | SEC EDGAR | -3.69% | -17.13% | |
| Form DEFA14A Tempest Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -3.69% | -17.13% | |
| Form 8-K Tempest Therapeutics, For: Sep 11 | SEC filing · Form 8-K | SEC EDGAR | +3.62% | +12.04% | |
| Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform | Press release | GlobeNewswire | +3.62% | +12.04% | |
| Tempest Therapeutics Announces Up to $7.5 Million Private Placement | Press release | GlobeNewswire | -3.09% | +2.75% | |
| Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference | Press release | GlobeNewswire | +0.98% | -3.22% | |
| Form EFFECT Tempest Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | +0.47% | -1.87% | |
| Form 8-K Tempest Therapeutics, For: Aug 18 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.00% | |
| Form S-1 Tempest Therapeutics, | SEC filing · Form S-1 | SEC EDGAR | -1.91% | +4.76% | |
| Form 8-K Tempest Therapeutics, For: Aug 17 | SEC filing · Form 8-K | SEC EDGAR | +2.94% | +4.90% | |
| Form DEFA14A Tempest Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +2.94% | +4.90% | |
| Form 10-Q Tempest Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.71% | -9.38% | |
| Form 8-K Tempest Therapeutics, For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | -2.71% | -9.38% | |
| Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | -2.71% | -9.38% | |
| Form 8-K Tempest Therapeutics, For: Jul 27 | SEC filing · Form 8-K | SEC EDGAR | -1.17% | +4.99% | |
| Form DEFA14A Tempest Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -1.17% | +4.99% | |
| Form 8-K Tempest Therapeutics, For: Jul 17 | SEC filing · Form 8-K | SEC EDGAR | -2.33% | -2.81% | |
| Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T | Press release | GlobeNewswire | -0.48% | +3.15% | |
| Form DEF 14A Tempest Therapeutics, For: Jul 27 | SEC filing · Form DEF | SEC EDGAR | -0.11% | -1.41% | |
| Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026 | Press release | GlobeNewswire | +1.93% | +9.08% | |
| Form EFFECT Tempest Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | -2.04% | +0.74% | |
| Form PRE 14A Tempest Therapeutics, For: Jul 27 | SEC filing · Form PRE | SEC EDGAR | -2.04% | +0.74% | |
| Form S-3 Tempest Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | -0.47% | +2.80% | |
| Form 8-K Tempest Therapeutics, For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | +2.37% | -0.40% | |
| Form D Tempest Therapeutics, | SEC filing · Form D | SEC EDGAR | +2.37% | -0.40% | |
| Form DEF 14A Tempest Therapeutics, For: Jun 18 | SEC filing · Form DEF | SEC EDGAR | +0.00% | +2.42% | |
| Form 8-K Tempest Therapeutics, For: May 29 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.78% | |
| Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors | Press release | GlobeNewswire | +0.00% | -0.78% | |
| Form 8-K Tempest Therapeutics, For: May 28 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -8.39% | |
| Form 8-K Tempest Therapeutics, For: May 23 | SEC filing · Form 8-K | SEC EDGAR | +0.01% | -5.23% | |
| Form PRE 14A Tempest Therapeutics, For: Jun 18 | SEC filing · Form PRE | SEC EDGAR | +0.01% | -5.23% | |
| Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds | Press release | GlobeNewswire | -7.49% | -8.38% | |
| Form 8-K Tempest Therapeutics, For: May 19 | SEC filing · Form 8-K | SEC EDGAR | -0.27% | -4.32% | |
| Form 8-K Tempest Therapeutics, For: May 22 | SEC filing · Form 8-K | SEC EDGAR | -0.27% | -4.32% | |
| Form 10-Q Tempest Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -6.90% | -8.50% | |
| Form 8-K Tempest Therapeutics, For: May 14 | SEC filing · Form 8-K | SEC EDGAR | -6.90% | -8.50% | |
| Tempest Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | -6.90% | -8.50% | |
| Form 8-K Tempest Therapeutics, For: May 06 | SEC filing · Form 8-K | SEC EDGAR | +0.93% | -5.16% | |
| Tempest Presents Clinical Update at ISCT 2026 Annual Meeting | Press release | GlobeNewswire | +0.93% | -5.16% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the TPST section they belong to.
Where else TPST is measured.
TPST earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Tempest Therapeutics, Inc.'s median reaction calculated?
Every labeled TPST news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 237 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 40% of TPST's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does TPST's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.